EVNIN LUKE sold $15K of HOWL (indirect holdings)

EVNIN LUKE sold 36,387 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.42 on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · EVNIN LUKE
Published May 26, 2026, 10:18 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HOWL
Neutral
medium confidence
Mentioned
$HOWL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HOWLNeutralLow
01

Why it matters

The disclosure provides transparency on director selling activity; however, the presence of a pre-arranged 10b5-1 plan generally lowers the probability that the trade signals new negative information.

02

Market read

Traders may briefly reassess insider activity sentiment, but absent other catalysts, the event is unlikely to drive a sustained repricing.

03

What to watch

Assess whether there are multiple recent insider transactions, changes in volume/price around the sale date, or concurrent company-specific catalysts not mentioned here.

Relevance 6/10Timing: Same-day/near-term attention as the Form 4 is filed; limited follow-through expected.

Background

The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc. (HOWL).

Company-level read

Ticker impact

$HOWLNeutralMedium confidence
Context

Werewolf Therapeutics director EVNIN LUKE sold 36,387 HOWL shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any move would be small and driven more by broader sentiment than this single sale.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 plan, and the disclosed value (~$15.3K) is not large enough to imply a fundamental change by itself.

Market effects

Minimal—single-company insider sale without accompanying operational or clinical news.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.

Key entities

  • Werewolf Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (HOWL).

  • EVNIN LUKE

    Director who executed an open-market sale of 36,387 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HOWLMedAI 8/10

Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou